System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Celeste Lebbé is an expert in Dermatology at Hôpital Saint-Louis (France). As of October 2026, ScienceLeadR ranks Celeste Lebbé in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Sarcoma. Celeste Lebbé has authored 1,196 publications, the most recent in 2026, and is an investigator in 76 clinical trials, 9 of them ongoing. SLR score: 4,350 (community average: 125). How the SLR is computed.

LeadR Profile

Celeste Lebbé Hôpital Saint-Louis France
4 350 ScienceLeadR Reputation 4350

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Hôpital Saint-Louis

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1196

Citations

Citations: 90 730 1st author: 56 Last author: 243 Unique author: 12

Main journals

Ann Dermatol Venereol 231
J Clin Oncol 131
Ann Oncol 82
Eur J Cancer 81
J Eur Acad Dermatol Venereol 29

Best Journals

J Clin Oncol 56
Ann Oncol 39
Lancet Oncol 17

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Current and emerging strategies for the management of brain and leptomeningeal metastases in melanoma.
PMID 42840607 — radiotherapy, blood, radiosurgery, melanoma, brain, immunotherapy, immune checkpoint inhibitors, neoplasm metastasis, therapeutics		Front Oncol20260
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
PMID 42823486 — cells, molecular biology, melanoma, neoplasm metastasis, neoadjuvant therapy, therapeutics		Nat Med Top journal20260
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.
PMID 42667537 — safety, melanoma, nivolumab, therapeutics		Dermatol Ther (Heidelb)20260
Correction: Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis.
PMID 42658469 — genomics, melanoma, skin diseases		Am J Clin Dermatol20260

Clinical Studies 76

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6 Study Director: 2

By phase:

Phase 2 27
Phase 3 23
Phase 1/Phase 2 10
N/A 8
Phase 1 6
Phase 2/Phase 3 2

By status:

Completed 35
Active not recruiting 11
Terminated 11
Unknown 10
Recruiting 7
Not yet recruiting 1
Suspended 1

By type:

Interventional 69
Observational 7

By Monocentric/Multicentric:

monocentric 18
multicentric2to4 1
multicentric5to9 6
multicentricup10 51

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical study of V940 and pembrolizumab in people with melanoma (V940 012)
2024-519605-36-00 — melanoma, rna, messenger		Phase 2Recruiting2025
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
NEOREM NEO 1 NEOREM Neo adjuvant Immunotherapy Master Trial for Localized Cancers NEO 1 Neo adjuvant immunotherapy in patients with localized melanoma
2025-522127-95-00 — quality of life, disease-free survival, melanoma, neoplasms, immunotherapy, therapeutics		Phase 2Recruiting2026
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
2023-506228-10-00 — cells, safety, carcinoma, squamous cell, melanoma, neoplasms, adenocarcinoma, drug-related side effects and adverse reactions, squamous cell carcinoma of head and neck, therapeutics, colorectal neoplasms, carcinoma, head, neck		Phase 1/Phase 2Active not recruiting2024
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS